Premium
B‐type natriuretic peptide and heart failure: what can we learn from clinical trials?
Author(s) -
BinounAEgom Christian,
Andreas Angelo,
Klimas Jan,
Valentova Vanda,
Kruzliak Peter,
Egom Emmanuel E
Publication year - 2015
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12418
Subject(s) - natriuresis , medicine , natriuretic peptide , diuresis , heart failure , clinical trial , intensive care medicine , cardiology , renal function
Summary The B ‐type natriuretic peptide ( BNP ) may favour natriuresis and diuresis, making it an ideal drug to aid in diuresing a fluid‐overloaded patient with poor or worsening renal function. Several randomized clinical trials have tested the hypothesis that infusions of pharmacological doses of BNP to acute heart failure ( HF ) patients may enhance decongestion and preserve renal function in this clinical setting. Unfortunately, none of these has resulted in a better outcome. The current challenge for BNP research in acute HF lies in a failure of concept and reluctance to abandon a demonstrably ineffectual research model. Future success will necessitate a detailed understanding of the mechanism of action of BNP as well as a better integration of basic and clinical science.